Literature DB >> 16332931

Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy.

Alaa S Awad1, Liping Huang, Hong Ye, Elizabeth Thu Anh Duong, W Kline Bolton, Joel Linden, Mark D Okusa.   

Abstract

We previously demonstrated the anti-inflammatory effects and renal tissue protection in response to adenosine A(2A)-receptor (A(2A)R) activation in acute renal injury. We sought to extend these studies and determine the efficacy of A(2A)R agonists in a chronic model of renal injury. We hypothesized that A(2A) agonists mediate renal tissue protection in diabetic nephropathy by reducing glomerular inflammation. Diabetes was induced with single intravenous injection of streptozotocin in Sprague-Dawley rats (50 mg/kg). Increases in urinary albumin excretion (UAE) and plasma creatinine at week 6 in the diabetes group (26- and 6-fold over control, respectively) were markedly reduced by continuous subcutaneous administration of ATL146e (10 ng x kg(-1) x min(-1)), a selective A(2A) agonist. The increase in UAE in the diabetes group was associated with a significant reduction in the expression of slit diaphragm-associated molecules compared with control (nephrin; P < 0.05 and podocin; P < 0.005) that was reversed by ATL146e treatment. Diabetes led to an increase in urinary excretion of monocyte chemoattractant protein-1 (705% of control), TNF-alpha (1,586% of control), IFN-gamma (298% of control), kidney fibronectin mRNA (457% of control), and glomerular infiltration of macrophages (764% of control), effects significantly reduced by ATL146e treatment. Mesangial expansion and basement membrane thickness were reduced with ATL146e. To further confirm the selectivity of ATL146e, we used wild-type (WT) or A(2A)knockout (A(2A)-KO) mice. Four weeks after diabetes, UAE increased significantly in both WT and A(2A)-KO diabetic mice (3.0- and 3.3-fold over control). A(2A) agonist treatment blocked the increase in UAE in WT diabetic mice (P < 0.001), whereas it had no effect on the A(2A)-KO diabetic mice. These results demonstrate that chronic A(2A)R activation in diabetic rats 1) ameliorates histological and functional changes in kidneys induced by diabetes and 2) causes reduced inflammation associated with diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16332931     DOI: 10.1152/ajprenal.00310.2005

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  62 in total

1.  Transcriptional analysis of infiltrating T cells in kidney ischemia-reperfusion injury reveals a pathophysiological role for CCR5.

Authors:  Gang Jee Ko; Douglas Linfert; Hye Ryoun Jang; Elizabeth Higbee; Tonya Watkins; Chris Cheadle; Manchang Liu; Lorraine Racusen; Dmitry N Grigoryev; Hamid Rabb
Journal:  Am J Physiol Renal Physiol       Date:  2011-12-07

2.  The effects of anti-inflammatory and anti-angiogenic DNA vaccination on diabetic nephropathy in rats.

Authors:  Peter Celec; Július Hodosy; Roman Gardlík; Michal Behuliak; Roland Pálffy; Marek Pribula; Peter Jáni; Ján Turňa; Katarína Sebeková
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

3.  A(₂A) adenosine receptor (A(₂A)AR) as a therapeutic target in diabetic retinopathy.

Authors:  Ahmed S Ibrahim; Mamdouh M El-Shishtawy; Wenbo Zhang; Ruth B Caldwell; Gregory I Liou
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

4.  Disruption of adenosine 2A receptor exacerbates NAFLD through increasing inflammatory responses and SREBP1c activity.

Authors:  Yuli Cai; Honggui Li; Mengyang Liu; Ya Pei; Juan Zheng; Jing Zhou; Xianjun Luo; Wenya Huang; Linqiang Ma; Qiuhua Yang; Shaodong Guo; Xiaoqiu Xiao; Qifu Li; Tianshu Zeng; Fanyin Meng; Heather Francis; Shannon Glaser; Lulu Chen; Yuqing Huo; Gianfranco Alpini; Chaodong Wu
Journal:  Hepatology       Date:  2018-05-10       Impact factor: 17.425

Review 5.  Recent developments in adenosine receptor ligands and their potential as novel drugs.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Biochim Biophys Acta       Date:  2010-12-23

6.  Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes.

Authors:  Alaa S Awad; Michael D Rouse; Konstantine Khutsishvili; Liping Huang; W Kline Bolton; Kevin R Lynch; Mark D Okusa
Journal:  Kidney Int       Date:  2011-02-02       Impact factor: 10.612

7.  Activation of adenosine 2A receptors preserves structure and function of podocytes.

Authors:  Alaa S Awad; Michael Rouse; Lixia Liu; Amy L Vergis; Diane L Rosin; Joel Linden; John R Sedor; Mark D Okusa
Journal:  J Am Soc Nephrol       Date:  2007-11-28       Impact factor: 10.121

8.  Cannabidiol arrests onset of autoimmune diabetes in NOD mice.

Authors:  Lola Weiss; Michael Zeira; Shoshana Reich; Shimon Slavin; Itamar Raz; Raphael Mechoulam; Ruth Gallily
Journal:  Neuropharmacology       Date:  2007-07-17       Impact factor: 5.250

9.  Macrophage A2A Adenosine Receptors Are Essential to Protect from Progressive Kidney Injury.

Authors:  Luan D Truong; Jessica Trostel; Rachel McMahan; Jiang-Fan Chen; Gabriela E Garcia
Journal:  Am J Pathol       Date:  2016-08-09       Impact factor: 4.307

10.  Adenosine A₂A receptor agonist-mediated increase in donor-derived regulatory T cells suppresses development of graft-versus-host disease.

Authors:  Kyu Lee Han; Stephenie V M Thomas; Sherry M Koontz; Cattlena M Changpriroa; Seung-Kwon Ha; Harry L Malech; Elizabeth M Kang
Journal:  J Immunol       Date:  2012-12-07       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.